Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): A clinical overview

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue SUPPL. 1, 2010, Pages 1-14

  Rzany, B ^a   Ascher, B ^b   Monheit, G D ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Clinique de Chirurgie Esthetique Iena   (France)

^c TOTAL   (France)

Author keywords

Botulinum toxin; Efficacy; Glabella; Safety

Indexed keywords

AZZALURE; BOTULINUM TOXIN A; NEUTRALIZING ANTIBODY; PLACEBO; UNCLASSIFIED DRUG;

ASTHENOPIA; BIOLOGICAL ACTIVITY; BLEPHAROSPASM; BLURRED VISION; CERVICAL DYSTONIA; CLINICAL ASSESSMENT; CLINICAL STUDY; CLINICAL TRIAL; DIPLOPIA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EYE MOVEMENT DISORDER; EYELID EDEMA; FACIAL NERVE PARALYSIS; GLABELLAR LINE; HEADACHE; HEMATOMA; HEMIFACIAL SPASM; HUMAN; INCIDENCE; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE STINGING; INJECTION SITE SWELLING; LACRIMATION; MULTIPLE CYCLE TREATMENT; MUSCLE TWITCH; PAIN; PATIENT SATISFACTION; PRIORITY JOURNAL; PRURITUS; PTOSIS; RASH; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN IRRITATION; SPASTICITY; TACHYPHYLAXIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; URTICARIA; VISUAL DISORDER; WRINKLE;

BOTULINUM TOXIN TYPE A; FACE; HUMANS; SKIN AGING;

EID: 72949123459     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03475.x     Document Type: Review

References (45)

1. Koussoulakos. Botulinum neurotoxin: the ugly duckling. Eur Neurol 2009 61 : 331 342.
2. Poulain B, Popoff M, Molgo J. How do botulinum neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. Botulinum J 2008 1 : 14 87.
3. Crouch ER. Use of botulinum toxin in strabismus. Curr Opin Ophthalmol 2006 17 : 435 440.
4. Jost WH, Kohl A. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 2001 248 (Suppl. 1 21 4.
5. Swope D, Barbano R. Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. Neurol Clin 2008 26 (Suppl. 1 54 65.
6. Carruthers J, Carruthers A. The evolution of botulinum neurotoxin type A for cosmetic applications. J Cosmet Laser Ther 2007 9 : 186 192. (Pubitemid 47351211)
7. de Maio M, Rzany B. Botulinum Toxin in Aesthetic Medicine. Springer, Heidelberg, 2007.
8. Ascher B, Landau M, Rossi B. Injection treatments in cosmetic surgery. Informa Healthcare, London, 2008.
9. Data on file. Azzalure® SmPC. Galderma Inc, 2008.
10. Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004 51 : 223 233.
11. Rzany B, Ascher B, Fratila A, Monheit G, Talarico S, Sterry W. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006 142 : 320 326.
12. Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 2007 33 : S51 9.
13. ®) in the treatment of glabellar lines (Study Y-97-52120-718).
14. Brandt F, Swanson N, Baumann L, Huber B Randomized, placebo-controlled study of a new botulinum toxin type A for treatment of glabellar lines: efficacy and safety. Accepted by Dermatol Surg.
15. Kane MA, Rohrich RJ, Narins RS, Monheit GD, Huber MB. Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase 3, randomized, double-blind, placebo-controlled study. Accepted by Plast Reconstr Surg.
16. Ascher B, Zakine B, Kestemont P et al. Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surg J 2005 25 : 365 375.
17. Moy R, Maas C, Monheit G, Huber B. Long-term safety and efficacy of a new botulinum toxin type A in treatment glabellar lines. Arch Facial Plast Surg 2009 11 : 77 83.
18. Rubin MG, Dover J, Glogau RG, Goldberg DJ, Goldman MP, Schlessinger J. The efficacy and safety of a new U.S. botulinum toxin type A in the re-treatment of glabellar lines following open-label treatment. J Drugs Dermatol 2009 8 : 439 444.
19. Monheit GD, Cohen JL. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study. J Am Acad Dermatol 2009 61 : 421 425.
20. Rzany B, Dill-Müller D, Grablowitz D, Heckmann M, Carid D. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4103 treatments in 945 patients. Dermatol Surg 2007 33 : S18 25.
21. Carruthers A, Carruthers J. A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytides: safety and efficacy. J Am Acad Dermatol 2009 60 : 972 979.
22. Data on file. Ipsen Ltd. A phase II, randomized, double-blind, placebo-controlled, dose-finding study to determine the optimal dose of 52120 in the treatment of glabellar lines (Study Y-97-52120-717). Part of the study results were published in reference 12.
23. ® in the treatment of glabellar lines (Study Y-97-52120-719). Data on file. Part of the study results were published in reference 14.
24. Lewis CM, Lavell S, Simpson MF. Patient selection and patient satisfaction. Clin Plast Surg 1983 10 : 321 332.
25. ®) in the treatment of glabellar frown lines (Study 2-54-52120-009). Part of the study results were published in reference 10.
26. Data on file. Ipsen Ltd. A phase III, multicentre, randomized, double-blind, placebo-controlled study of efficacy and safety of 2 injections with 50 Speywood Units of botulinum toxin A Ipsen in the treatment of glabellar frown lines (Study 2-54-52120-046). Part of the study results were published in reference 16.
27. Data on file. Ipsen Ltd. Retrospective survey of the effectiveness and safety of repeated injections of Botulinum toxin A Ipsen (Dysport) in aesthetic medicine (Study A-94-52120-728). Data on file. Part of the study results were published in reference 20.
28. de Boulle K. Patient satisfaction with different botulinum toxin type A formulations in the treatment of moderate to severe upper facial ryhtides. J Cosmet Laser Ther 2008 10 : 87 92.
29. Pickett A, Rzany B. Botulinum toxin in aesthetic applications: 'how often misused words generate misleading thoughts'. (Response to: De Boulle K. Patient satisfaction with different botulinum toxin type A formulations in the treatment of moderate to severe upper facial rhytides. J Cosmet Laser Ther 2009 10 : 87 92. J Cosmet Laser Ther 2009; 11: 178-179; author reply 180-181.
30. Honeck P, Weiss C, Sterry W, Rzany B. Reproducibility of a four-point clinical severity score for glabellar from lines. Br J Dermatol 2003 149 : 306 310.
31. Carruthers JA, Lowe NJ, Menter MA et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatology 2002 46 : 840 849.
32. Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003 112 : 1089 1098.
33. Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg 2005 31 : 1297 1303.
34. Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 2005 31 : 414 422.
35. Harii K, Kawashima M. A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treatment glabellar lines in Japanese subjects. Aesthetic Plast Surg 2008 32 : 724 730.
36. Grimes PE, Shabazz D. A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI. Dermatol Surg 2009 35 : 429 435.
37. ® SmPC. Ipsen Ltd, 2007.
38. Haussermann P, Marczoch S, Klinger C et al. Long-term follow-up of cervical dystonic patients treated with botulinum toxin A. Mov Disord 2004 19 : 303 308.
39. Jitpimolmard S, Tiamkao S, Laopaiboon M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry 1998 64 : 751 757.
40. Rubin M, Dover J, Maas C et al. An analysis of safety data from 5 Phase 3 clinical trials on the use of BoNT-A for the treatment of galbellar lines. Accepted by Aesthet Surg J.
41. Trindade de Almeida AR, Marque E, de Almerida J, Cunha T, Borasco R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 2007 33 (Suppl. S37 43.
42. Hexsel D, Dal'Forno T, Hexsel C et al. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg 2008 34 : 52 9.
43. Wagman J, Bateman JB. Botulinum type A toxin: properties of a toxic dissociation product. Arch Biochem Biophys 1953 45 : 375 383.
44. ®: pharmacological properties and factors that influence toxin action. Toxicon 2009, Epub ahead of print.
45. Lawrence I, Moy R. An evaluation of neutralizing antibody induction during BoNT-A treatment. Accepted by Aesthet Surg J.